Theme: Care about Gastrointestinal cancer for healthy lifestyle

GI Cancer 2017

GI Cancer 2017

ConferenceSeries Ltd invites all the participants across the globe to attend ‘International Conference on Gastrointestinal Cancer and Therapeutics’ during October16-18, 2017 at Baltimore, USA. which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

ConferenceSeries Ltd, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe

Gastrointestinal Cancer 2017 provide you the best opportunity to reach the largest assemblage of participants from the cancer meeting, oncology society, European oncology conferences, surgical oncology, global cancer conference to Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition of your research work. World-renowned speakers, the most recent techniques, developments, the newest updates and advancements in Pancreatic cancer, Colorectal Cancer, Liver cancer, Stomach cancer, Esophageal cancer, and Gall bladder cancer are hallmarks of this event.

Our cancer conferences also provides members and participants from major societies like American oncology society, European Society for Medical Oncology, Canadian cancer society, Colorectal Cancer Association of Canada – CCAC.

Gastrointestinal Cancer 2017 will mainly focus on the Cause of the cancer its Symptoms, Diagnosis, Treatment, Tests, Pathogenesis, Surgical and Non-Surgical Methods, Signs & Symptoms, Diagnosis, Chemotherapy ,Surgery and Immunotherapy of Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumors, Gall Bladder Cancer, Oncology Nursing and Primary care, Imaging and Gastrointestinal Cancer, Cancer pharmacology

Track 1: Gastrointestinal Cancer

Gastro-Intestinal (GI) cancer is a term for the group of cancers that affect the digestive system. Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestive system. Cancer arises in chronically inflamed gastrointestinal tissues and organs like esophagus, stomach, liver, pancreas, gallbladder, Colon, rectum and anus is called Gastrointestinal Cancer. The symptoms relate to the organ affected can include obstruction (leading to difficulty swallowing or defecating), abnormal bleeding or other associated problems. The most commonly used screening is colonoscopy Patients with gastrointestinal cancer can be treated with interventional endoscopy, radiation, chemotherapy, immunotherapy, surgery, targeted therapies or a combination of these.

Related Conference

Oral, Mouth and Throat Cancer August 15-17, 2016 Portland, Oregon, USA. Cervical Cancer and Therapeutics August 04-05, 2016 Manchester, UK. Radiation Oncology November 21-22, 2016 Dubai, UAE. Multiple Myeloma conference Oct 15-17, 2017 Milano, Italy. Surgical Oncology October 03-05, 2016 Atlanta, Georgia, USA.2017.Annual Meeting of The Association of Coloproctology of Great Britain & Ireland 3rd July – 5th July 2017 Bournemouth International Centre,UK. AACR Colorectal Cancer: From Initiation to Outcomes September 17-20, 2016 Tampa, Florida. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. St Mark's 14th Annual International Congress: Frontiers In Intestinal And Colorectal Disease 2016 November 22, 2016 - November 25, 2016 Harrow , United Kingdom. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom. 6th Enhanced Recovery After Surgery Society (U.k) Conference 2016 NOVEMBER 4, 2016 Cardiff , United Kingdom. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. 4th International Controversies in Rectal Cancer Conference 14^th –15^th September 2016 Colchester, Essex, U.K.

12^th Oncology Conferences Europe September 26-28, 2016 London, UK, 12^th Cancer Science Events Europe September 26-28, 2016 London, UK, Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE, Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK

Track 2: Colorectal Cancer

Colorectal cancer is a term for cancer that starts in either the colon or the rectum. Colon cancer and rectal cancer have many features in common. Colon cancer and cancer of the rectum can begin as a small polyp, detectable through regular cancer screening, such as colonoscopy. Colon cancer symptoms include a change in bowel habits like bleeding or blood in stools, but often there are no symptoms. With early detection, surgery, radiation, and/or chemotherapy can be effective treatment. Rectal cancer begins in the rectum. It’s also called colorectal cancer because it can occur above the rectum, in the colon or in the rectum. Some people are at higher risk because of a family history of certain genetic disorders such as Lynch syndrome. Colon cancer is a type of cancer that begins in the colon, an organ that is part of the large intestine and the body’s digestive system. Small intestine cancer, also known as small bowel cancer, begins in cells of the small intestine, the part of the digestive system located between the stomach and large intestine. It’s rare, affecting about 9,000 people a year in the United States.

Related Conferences:

Surgical Oncology Conference October 03-05, 2016 Atlanta, Georgia, USA. 14th World Cancer Therapy Congress December 05-07, 2016 Philadelphia, Pennsylvania, USA.13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE.Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. Spring Colorectal Meeting New Zealand September 14 - 17, 2016. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth.

Track 3: Pancreatic Cancer

Pancreatic cancer is a disease in which malignant (cancerous) cells form in the tissues of the pancreas. The pancreas is a gland located behind the stomach and in front of the spine. The pancreas produces digestive juices and hormones that regulate blood sugar. Cells called exocrine pancreas cells produce the digestive juices, while cells called endocrine pancreas cells produce the hormones. Pancreatic cancer begins when abnormal cells within the pancreas grow out of control and form a tumour. The majority of pancreatic cancers start in the exocrine cells. Your pancreas secretes enzymes that aid digestion and hormones that help regulate the metabolism of sugars. Pancreatic neuroendocrine tumours (pancreatic NETs or PNETs) account for less than 5% of all pancreatic tumours. They may be benign or malignant and they tend to grow slower than exocrine tumours. They develop from the abnormal growth of endocrine (hormone-producing) cells in the pancreas called islet cells. This is why these tumours are sometimes referred to as “islet cell tumours”. Pancreatic cancer often has a poor prognosis, even when diagnosed early. Pancreatic cancer spreads rapidly and is seldom detected in its early stages, which is a major reason why it's a leading cause of cancer death. Signs and symptoms may not appear until pancreatic cancer is quite advanced and complete surgical removal isn't possible.

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia.12th World Cancer Conference September 26-28, 2016 London, UK. Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA .7th International Conference and Expo on Molecular & Cancer Biomarkers September 15-16, 2016 Berlin, Germany. Conference on Leukemia and Bone Marrow Transplantation October 17-18, 2016. Rome,Italy. International Society Of University Colon And Rectal Surgeons (ISUCRS 2016) Mumbai, India,23rd - 25th September 2016. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City,Japan. 8th European Multidisciplinary Colorectal Cancer Congress 11 - 13 december 2016 RAI Amsterdam Netharland.15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States. 4th International Controversies in Rectal Cancer Conference 14^th – 15^th September 2016 ICENI Centre Colchester Hospital, Colchester, Essex C04 5JL U.K.

Track 4: Liver Cancer

Liver cancer is the abnormal growth of liver cells in the liver. Cancer begins in the hepatocytes, the main type of liver cell, other liver cell types infrequently can become cancerous but the most common liver cancer is hepatocellular cancer. Cancer cells can then become destructive to adjacent normal tissues, and can spread both to other areas of the liver and to organs outside the liver. Hepatocellular carcinoma is the most common form of liver cancer in adults. Cancerous cells that arises in the ducts of the liver is called cholangiocarcinoma. The leading cause of liver cancer is cirrhosis due to either hepatitis B, hepatitis C or alcohol.

Related Conferences:

Surgical Oncology Conference October 03-05, 2016 Atlanta, Georgia, USA. 14th World Congress on Cancer Therapy December 05-07, 2016 Philadelphia, Pennsylvania, USA.13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE.Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. Spring Colorectal Meeting New Zealand September 14 - 17, 2016. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016.

Track 5: Esophageal Cancer

Esophageal cancer is cancer that occurs in the esophagus, a long hollow muscular tube which runs from your throat to your stomach that moves food and liquids from the throat to the stomach. Cancer starts at the inner layer of the esophagus and can spread throughout the other layers of the esophagus and to other parts of the body (metastasis). The most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma begins in flat cells lining the esophagus. Adenocarcinoma begins in cells that make and release mucus and other fluids. Esophageal cancer is often diagnosed at an advanced stage because there are no early signs or symptoms.

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016

Track 6: Stomach Cancer

Stomach cancer starts when cancer cells form in the inner lining of the stomach. These cells can grow into a tumor also called gastric cancer, most commonly, gastric cancers originate in the mucosa of the stomach, and disease usually grows slowly over many years. Early symptoms may include heartburn, upper abdominal pain, nausea and loss of appetite. Later signs and symptoms may include weight loss, yellowing of the skin and whites of the eyes, vomiting, difficulty swallowing, and blood in the stool among others. The cancer may spread from the stomach to other parts of the body, particularly the liver, lungs, bones, lining of the abdomen and lymph nodes.

Related Conferences:

Oral, Mouth and Throat Cancer August 15-17, 2016 Portland, Oregon, USA. Cervical Cancer and Therapeutics August 04-05, 2016 Manchester, UK. Radiation Oncology November 21-22, 2016 Dubai, UAE. Myeloma Conference Oct 15-17, 2017 Milano, Italy. Surgical Oncology October 03-05, 2016 Atlanta, Georgia, USA.2017. Annual Meeting of The Association of Coloproctology of Great Britain & Ireland 3rd July – 5th July 2017 Bournemouth International Centre,UK. AACR Colorectal Cancer: From Initiation to Outcomes September 17-20, 2016 Tampa, Florida. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. St Mark's 14th Annual International Congress: Frontiers In Intestinal And Colorectal Disease 2016 November 22, 2016 - November 25, 2016 Harrow , United Kingdom. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom. 6th Enhanced Recovery After Surgery Society (U.k) Conference 2016 NOVEMBER 4, 2016 Cardiff , United Kingdom. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. 4th International Controversies in Rectal Cancer Conference 14^th – 15^th September 2016 Colchester, Essex, U.K.

Track 7: Gastrointestinal Stromal Tumors

A gastrointestinal stromal tumor (GISTs) is a disease in which abnormal cells form in the tissues of the gastrointestinal tract. Gastrointestinal stromal tumors are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs arise in the smooth muscle pacemaker interstitial cell of Cajal, which is more common in the stomach and small intestine but may be found anywhere in or near the GI tract.

Related Conferences:

2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA. Lymphoma July 24-26, 2017 Rome, Italy. 13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia.14th World Congress on Cancer Therapy December 05-07, 2016 Philadelphia, Pennsylvania, USA.5th Radiology and Imaging September 19-20, 2016, Las Vegas, Nevada, USA. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States.

Track 8: Gall Bladder Cancer

Gallbladder cancer is cancer that begins in the gallbladder or in the bile ducts, which are thin tubes that carry bile from the liver. It is a rare cancer that is thought to be related to gallstones building up, which also can lead to calcification of the gallbladder, a condition known as porcelain gallbladder. Porcelain gallbladder is also very rare. Few studies indicate that people with porcelain gallbladder have a high risk of developing gallbladder cancer.

Related Conferences:

Radiation Oncology November 21-22, 2016 Dubai, UAE.12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom.

Track 9: Gastrointestinal Cancer: Signs & symptoms

Signs and symptoms of gastrointestinal cancer includes nausea, vomiting, frequent heartburn, loss of appetite (sometimes accompanied by sudden weight loss), early satiety (feeling full after eating only a small amount), bloody stools, jaundice (a yellowish discoloration in the eyes and skin),excessive fatigue,Weight loss not associated with changes in diet, enlarged liver, stomach pain (which may be worse after meals)

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 7th International Conference and Expo on Molecular & Cancer Biomarkers, September 15-16, 2016 Berlin, Germany. Conference on Lymphoma July 24-26, 2017 Rome, Italy. 58th ASH Annual Meeting & Exposition, Dec 2016 California, USA, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8, 2016 - December 10, 2016 Orlando , United States.

Track 10: Gastrointestinal Cancer: Causes

Generally, cancer begins when a mutation occurs in a cell's DNA. This mutation causes the cell to grow and divide at a rapid rate and to continue living when a normal cell would die. The accumulating cancerous cells form tumor that can invade nearby structures The causes of general Gastrointestinal cancer problems are constipation, diarrhea, nausea and vomiting vary widely malabsorption disorders, gastroenteritis (inflammation of the stomach and small intestine due to viral or bacterial infection from contaminated food, colitis (inflammation of the large intestine that may be triggered by certain foods or bacterial infections), Ulcers in the stomach. Taking certain medicines (especially antidepressants, iron pills, and strong pain medicines such as narcotics) also causes gastrointestinal cancer.

Related Conference

Track 11: Gastrointestinal Cancer: Diagnosis

To make a definitive way of diagnosis of most types of gastrointestinal cancers, a biopsy is preferred. If a biopsy is not possible, the doctor may suggest other tests that will help make a diagnosis. Imaging tests may be used to find out whether the cancer has spread. Early diagnosis of gastric cancer is difficult because most patients are asymptomatic in the early stage. Esophagogastroduodenoscopy is the preferred diagnostic modality for evaluation of patients in whom stomach cancer is suspected. This radiographic study provides preliminary information that may help the physician determine if a gastric lesion is present and whether the lesion has benign or malignant features.

Related Conferences:

Radiation Oncology Conference, November 21-22, 2016 Dubai, UAE; 7th International Conference and Expo on Molecular & Cancer Biomarkers, September 15-16, 2016 Berlin, Germany; 8th Annual Pharma Middle East Congress, October 10-12, 2016 Dubai, UAE; 2nd World Congress and Exhibition on Antibiotics and Antibiotic Resistance, October 13-15, 2016 Manchester, UK; 2nd Drug Discovery Conference , November 08-09, 2016 Istanbul, Turkey; AACR -Tumor Immunology and Immunotherapy Conference, October 20-23, 2016 Boston, USA; ESMO 2016 Congress, October 07-10, 2016 Copenhagen, Denmark; Paediatric Academic Society Conference, May 6–9, 2017, California, USA; AACR International Conference on New Frontiers in Cancer Research, January 18-22, 2017 Cape Town, South Africa; World Cancer Congress 2016, Oct 31- Nov 03, 2016 Paris, France; 58th ASH Annual Meeting & Exposition, Dec 2016 California, USA; San Antonio Breast Cancer Symposium, December 6-10, 2016 San Antonio, Texas; 17th World Conference on Lung Cancer 2016, Dec 04-07, 2016 Vienna, Austria; 12^th Oncology Conferences Europe September 26-28, 2016 London, UK; 12^th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK

Track 12: Gastrointestinal Cancer: Treatment & Management

Treatment options and recommendations depend on several factors, including the type and stage of cancer, possible side effects, and the patient’s preferences and overall health issues. The most common treatment in different types of gastrointestinal cancers is surgery and radiation therapy. The treatment for esophageal cancer is particularly Tis and T1aN0 by endoscopic ultrasonography may be considered for endoscopic therapy,

New therapeutic strategies with the established treatment regimens are most important and very much needed in gastrointestinal cancer it represents a novel approach to the management of different types of gastrointestinal cancer, so the pathological development of vascular supply is a major step for tumor growth and may affect its prognosis.

Related Conferences:

Track 13: Gastrointestinal Cancer: Pathogenesis

Pathogenesis of Colorectal Cancer: Sporadic (Nonhereditary) Colorectal Cancer is detected through screening procedures or when the patient presents with symptoms. Screening is important for prevention and should be a part of routine care for adults over the age of 50 who are at low-risk. High-risk individuals (those who are with previous colon cancer, those who have family history of colon cancer, and those who have inflammatory bowel disease or history of colorectal polyps) require careful follow-up. Major advances have been made in our understanding of molecular events leading to the formation of adenomatous polyps and cancer most of the colorectal cancers are sporadic.

Related Conference:

8th International Conference on Biomarkers , December 05-07, 2016, Philadelphia, USA; 7th International Conference and Expo on Molecular & Cancer Biomarkers, September 15-16, 2016 Berlin, Germany; 6th International Conference on Genomics September 22-24, 2016 Germany; 5th International Conference on Translational Medicine , November 17-19, 2016 USA; Asia Pacific Mass Spectrometry Congress October 13-15, 2016 Kuala Lumpur, Malaysia; 36th Congress of ESSO with the PSSO, Sep 14 -16 Sep 2016 Cracow, Poland; EOC2016 — 5th Emirates Oncology Conference 2016, Nov 17 - 19 2016, Abu Dhabi, UAE ; Paediatric Academic Society Conference, May 6–9, 2017, California, USA; AACR-New Horizons in Cancer Research, November 2-5, 2016 Shanghai, China; ; 6th International Conference on Pharmacogenomics, September 22-24, 2016 Germany; 8^th International Conference on Clinical Research, December 05-07, 2016, Philadelphia, USA; 58th ASH Annual Meeting & Exposition, Dec 2016 California, USA; The 26th World Congress of the IASGO, September 08-10, 2016 Seoul, South Korea; 8th Annual UAE Cancer Congress Oct 20-22, 2016 Dubai, UAE;American Society of Clinical Oncology 2017 Annual Meeting, June 02-06, 2017 Chicago, USA; 12^th Oncology Conferences Europe September 26-28, 2016 London, UK; 12^th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK

Track 14: Biomarkers

A cancer biomarker can be a process substance that indicates the presence of cancer in the body. It may be a molecule secreted by tumor cells or a particular response of the body because of the presence of cancer. Biomarkers may genetic, epigenetic, proteomic, glycomic, or imaging. They can be used for cancer diagnosis, prognosis, medicine, epidemiology of cancer. Those biomarkers that are particularly associated with mutations offer a quantitative way to determine when individuals are predisposed to particular types of cancers.

Related Conferences:

12^th Cancer Science Events Europe September 26-28, 2016 London, UK .12th World Cancer Conference September 26-28, 2016 London, UK.2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA . Neuroendocrine Cancer Conference, Nov 7-9, 2016 Las Vegas, USA. International Conference on Internal Medicine, November 03-05, 2016 USA. International Society Of University Colon And Rectal Surgeons (ISUCRS 2016) Mumbai, India,23rd - 25th September 2016. AACR International Conference on New Frontiers in Cancer Research, January 18-22, 2017 Cape Town, South Africa ; American Society of Clinical Oncology 2017 Annual Meeting, June 02-06, 2017 Chicago, United States 8th European Multidisciplinary Colorectal Cancer Congress 11 - 13 december 2016 RAI Amsterdam Netharland.15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States. 4th International Controversies in Rectal Cancer Conference 14th September – 15th September 2016 ICENI Centre Colchester Hospital, Colchester, Essex C04 5JL U.K.

Track 15: Chemotherapy

Chemotherapeutic agent is the agent used to treat cancer administered in regimens of one or more cycles, combining two or more agents over a period of days to weeks. Intravenous chemotherapy is one way to receive cancer-fighting medicine. Oral chemotherapy is a treatment used to shrink a tumor or kill cancer cells. Arterial chemotherapy infusion of the liver and chemoembolization of the liver are similar procedures that are used for the treatment of cancers in the liver. Adjuvant therapy or care, also called adjunct therapy or adjunctive therapy or care, is therapy that is given in addition to the primary, main, or initial therapy to maximize its effectiveness. Topical chemotherapy is a cream or lotion applied directly to the skin cancer. Different drugs cause different side effects. Certain types of chemotherapy often have specific side effects. But, each person’s experience is different.

Related Conferences:

12^th World Cancer Conference, September 26-28, 2016 London, UK; Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; ; Leukemia Conference October 17-18, 2016, Italy;13^th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14^th World Cancer Convention, November 21-23, 2016 Dubai ,UAE; 18^th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore; ; Leukemia Conference October 17-18, 2016, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Italy; European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November 3, 2016,France; NCRI Cancer Conference, November 6-9, 2016, London, UK;12^th Oncology Conferences Europe September 26-28, 2016 London, UK;12^th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016,Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai,

Track 16: Surgery

GI surgery includes comprehensive surgical methods used for the treatment of cancers and benign conditions of the esophagus, liver, colorectal, bile ducts, pancreas, stomach and gallbladder. Most of the surgical techniques are performed laparoscopically with the least invasive techniques reducing the post treatment risks.

Related Conferences:

Track 17: Immunotherapy

Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways: Own immune system stimulation, Biological therapy or biotherapy. Additional research is currently under way to: understand why immunotherapy is effective in some patients but not in other’s who have the same cancer, expand the use of immunotherapy to more types of cancer, increase the effectiveness of immunotherapy by combining it with other types of cancer treatment, such as targeted therapy, chemotherapy, and radiation therapy.

Related Conferences:

RadiationOncologyNovember21-22,2016Dubai,UAE.12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. 2nd World Congress and Exhibition on Antibiotics and Antibiotic Resistance. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress, 29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills:Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology 4-6 November 2016 Lausanne, Switzerland. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom.

Track 18: Gastrointestinal Cancer: Risk Factor and Prevention

Different gastrointestinal cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed. Having a risk factor, or even several risk factors, does not mean that you will get the cancer. And many people who get the disease may have few or no known risk factors. Few gastrointestinal cancer risk factors include cigarette smoking, obesity, chronic pancreatitis, eating foods preserved through pickling or that contain nitrates, infection with Helicobacter pylori, alcohol abuse, inflammatory bowel disease, adenomatous polyps

While no cancer is completely preventable, the number of new cases of cancer in a group or population is lowered. Hopefully, this will lower the number of deaths caused by cancer. It is estimated that changes in diet and physical activities could reduce the incidence of gastrointestinal Cancer by up to 75%.

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington ,United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. Worldwide Cancer Events November 21-23, 2016 Dubai, UAE.

Track 19: Oncology Nursing and Primary care

With the current challenges in the healthcare system, patients and professionals are uncertain about the role, responsibilities, and communication patterns of primary care professionals during cancer care. Oncology and primary care nurses should be surveyed to attain current and preferred roles in cancer care across the care continuum. Who coordinates the care, which makes the referrals, who manages the comorbidities? What is the optimal interface between oncology and primary care nurses in care delivery? How does the environment of care support or impede bidirectional communication among providers and with the patient? We need to test interventions to determine what model produces the best patient-centered outcomes, the best coordinated care. We need to document that coordinated care improves outcomes

Related Conferences:

5th Radiology and Imaging September 19-20, 2016, Las Vegas, Nevada, USA. Surgical Oncology October 03-05, 2016 Atlanta, Georgia, USA. 2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Paediatric Academic Society Conference, May 6–9, 2017, California, USA, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States.

Track 20: Imaging and Gastrointestinal Cancer:

Gastrointestinal tract imaging uses a form of real-time x-ray called fluoroscopy and a barium-based contrast material to produce images of the esophagus, stomach, small and large intestine and other parts of digestive system. It is safe, noninvasive and is used to help diagnose pain, acid reflux, blood in the stool and other symptoms.

Related Conferences:

Track 21: Cancer of pharma Industry

Cancer of pharma industry reached $100 billion in annual sales, and could reach $147 billion till 2018 cancer of pharma industry is probably the most prosperous business in the United States. New cancer cases diagnosed and death by cancer reaches 585,720 in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, with a projected 39 percent increase to $173 billion by 2020. Pharma industry for cancer is growing very aggressively with many opportunities.

Related Conferences:

Track 22: Gastrointestinal Cancer: Case Reports

Gastrointestinal Cancers case reports play a crucial role in moving new treatments to patients who need most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Oncology Esthetics is the practice of safe and beneficial spa services by individuals trained to understand how colorectal cancer and associated medical treatments affect the body. Gastrointestinal Oncology Nutrition includes the current therapies used to treat the cancer and nutrition related side effects. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients. If a patient with colorectal carcinoma develops metastatic disease of musculoskeletal oncology, the bone lesion may become dense and hard. There are currently more than several Phase III drug trials and more than 90 Phase I/II trials in process for colorectal cancer sin USA and Germany.

Related Conferences:

2nd Prostate Cancer and Therapeutics August 22-23, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. 13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia.14th World Cancer Therapy December 05-07, 2016 Philadelphia, Pennsylvania, USA.5th Radiology and Imaging September 19-20, 2016, Las Vegas, Nevada, USA. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. AACR Methods in Clinical Cancer Research Workshop July 29-August 4, 2017. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. European Colorectal Congress 2016 November 29, 2016 - December 2, 2016,St.Gallen , Switzerland. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8- 10, 2016 Orlando , United States.

Track 23: Entrepreneurs Investment Meet

A key ingredient in successful entrepreneurship is self-knowledge. Gastrointestinal Cancer 2016 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in Oncological community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. Although life scientists are typically the founders of biotech companies, studies have shown that the most successful high tech start-ups are founded by a team of two to three individuals with mixed backgrounds, substantial industry experience and a very clear market and product focus at founding. This two day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from oncology to signaling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts. The speakers will discuss about all the various topics of Gastrointestinal Cancers. Moreover, oncologists often develop an interest and expertise in the management of particular types of gastrointestinal cancer.

ConferenceSeries Ltd invites all the participants across the globe to attend ‘International Conference on Gastrointestinal Cancer and Therapeutics’ during October 31-November 1, 2016 at Toronto, Canada which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Track 1: Gastrointestinal Cancer

Related Conference

Track 2: Colorectal Cancer

Related Conferences:

Track 3: Pancreatic Cancer

Related Conferences:

Track 4: Liver Cancer

Related Conferences:

Track 5: Esophageal Cancer

Related Conferences:

Track 6: Stomach Cancer

Related Conferences:

Oral, Mouth and Throat Cancer August 15-17, 2016 Portland, Oregon, USA. Cervical Cancer and Therapeutics August 04-05, 2016 Manchester, UK. Radiation Oncology November 21-22, 2016 Dubai, UAE. Myeloma Conference Oct 15-17, 2017 Milano, Italy. Surgical Oncology October 03-05, 2016 Atlanta, Georgia, USA.2017. Annual Meeting of The Association of Coloproctology of Great Britain & Ireland 3rd July – 5th July 2017 Bournemouth International Centre,UK. AACR Colorectal Cancer: From Initiation to Outcomes September 17-20, 2016 Tampa, Florida. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. St Mark's 14th Annual International Congress: Frontiers In Intestinal And Colorectal Disease 2016 November 22, 2016 - November 25, 2016 Harrow , United Kingdom. Dilemmas & Debates In Colorectal Surgery 2016 November 8- 12, 2016 London , United Kingdom. 6th Enhanced Recovery After Surgery Society (U.k) Conference 2016 NOVEMBER 4, 2016 Cardiff , United Kingdom. 15th International Workshop on Multiple Endocrine Neoplasia and Other Rare Endocrine Tumours 29-1 September,2016 Utrecht, Netherlands. 4th International Controversies in Rectal Cancer Conference 14^th – 15^th September 2016 Colchester, Essex, U.K.

Track 7: Gastrointestinal Stromal Tumors

Related Conferences:

Track 8: Gall Bladder Cancer

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 7th International Conference and Expo on Molecular & Cancer Biomarkers, September 15-16, 2016 Berlin, Germany. Conference on Lymphoma July 24-26, 2017 Rome, Italy. 58th ASH Annual Meeting & Exposition, Dec 2016 California, USA, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington , United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. Advances In Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference 2016 December 8, 2016 - December 10, 2016 Orlando , United States.

Track 10: Gastrointestinal Cancer: Causes

Related Conference

Track 11: Gastrointestinal Cancer: Diagnosis

Related Conferences:

Track 12: Gastrointestinal Cancer: Treatment & Management

Related Conferences:

Track 13: Gastrointestinal Cancer: Pathogenesis

Related Conference:

Track 14: Biomarkers

Related Conferences:

Track 15: Chemotherapy

Related Conferences:

Track 16: Surgery

Related Conferences:

Track 17: Immunotherapy

Track 18: Gastrointestinal Cancer: Risk Factor and Prevention

Related Conferences:

13th Oncologists Annual Meeting October 17-19, 2016 Kuala Lumpur, Malaysia. 12th World Cancer Conference September 26-28, 2016 London, UK. 14th World Cancer Convention November 21-23, 2016 Dubai, UAE. 8th Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA. Lymphoma Conference July 24-26, 2017 Rome, Italy. Japan Society Of Coloproctology 71st Annual Meeting November 18-19, 2016 Ise City, Japan, International Society Of Gastrointestinal Oncology Conference 2016 October 22-23, 2016 Arlington ,United States. Sydney Colorectal Surgical Meeting19-11-2016,Sydney, Australia.10th Colorectal Cancer Conference – A Multidisciplinary Approach August18-19, 2016.10th European Colorectal Congress,29-11-2016 - 02-12-2016 St Gallen, Switzerland. Core Skills: Advanced Laparoscopic Colorectal Skills Workshop,November 25,2016,University of Western Australia, Perth. 4th ESMO Symposium on Immuno-Oncology Lausanne, Switzerland; 4-6 November 2016. Worldwide Cancer Events November 21-23, 2016 Dubai, UAE.

Track 19: Oncology Nursing and Primary care

Related Conferences:

Track 20: Imaging and Gastrointestinal Cancer:

Related Conferences:

Track 21: Cancer of pharma Industry

Related Conferences:

Track 22: Gastrointestinal Cancer: Case Reports

Related Conferences:

Track 23: Entrepreneurs Investment Meet

OMICS International cordially invites all the participants across the globe to attend the “International conference on Gastrointestinal Cancer and Therapeutics” October 16-18, 2017 at Baltimore, USA.

GI cancer 2017 will mainly focus on the advancements in the treatment of Gastrointestinal cancer and also addresses the recent developments in the surgical oncology of gastrointestinal cancer. This will be a most prominent global cancer conference where the eminent personalities dealing with the current research works on oncology and specialists in treatment of different types of cancers will discuss and create awareness on risk factors management of cancer. This cancer meeting also discuss the practical challenges encountered and the possible key solutions that can be adopted for treating Gastrointestinal Cancer.

Gastrointestinal cancer is the 3rd most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers). It is the 2nd leading cause of death from cancer in men and the 3rd leading cause of death from cancer in women in Canada. It is estimated that in 2015 that 25,100 Canadians will be diagnosed with gastrointestinal cancer. This represents 13% of all new cancer cases in 2015.9,300 Canadians will die from gastrointestinal cancer. This represents 12% of all cancer deaths in 2015.14,000 men will be diagnosed with colorectal cancer and 5,100 will die from it.11,100 women will be diagnosed with gastrointestinal cancer and 4,200 will die from it. On average, 69 Canadians will be diagnosed with gastrointestinal cancer every day. On average, 25 Canadians will die from gastrointestinal cancer every day. In both men and women, gastrointestinal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death and the second leading cause when both sexes are combined.

ConferenceSeries Ltd is a pioneer and leading scientific event organizer, publishing around 700+ Open access journals and conducting over 500 Scientific Meetings all over the globe annually with the support of more than 1000 scientific associations, 80,000 editorial board members, and 7.5 million followers to its credit. OMICS International hosts numerous Cancer Conferences, Cancer meeting, global cancer conference, European Oncology Conferences, Surgical oncology like skin cancer conference, colorectal cancer conference, breast cancer conference, liver cancer conference, lung cancer meetings, and Oncology Conferences where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions and which helps get possibilities for treating the diseases with new era, technology and research.

Why to attend?
With members from around the world focused on learning about Gastrointestinal Cancer, this is your best opportunity to reach the largest assemblage of participants from the Gastrointestinal Cancer community, Oncologists community, oncology society, European oncology conferences, American oncology society, Canadian Cancer society. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with advanced treatments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Gastrointestinal Cancer are the hallmarks of this conference.

Target Audience

Scientists
Students
Cancer Researchers
Faculty
Gastrointestinal Cancer Associations and Societies
Pancreatic Cancer Associations and Societies
Colon Cancer Associations and Societies
Rectal Cancer Associations and Societies
Business Entrepreneurs
Training Institutes
Pharmaceutical Companies
Biotechnology Companies
Biomedical Companies
Medical Devices Companies

Summary:

Colorectal cancer is a word used for cancer that starts in the colon or the rectum. These cancers can also be referred separately as colon cancer or rectal cancer, depending upon where they start. Colon cancer and the rectal cancer have many characters in common. Most of the colorectal cancers develop slowly over several years. Before the development of a cancer, a growth of tissue or tumour generally begins as a non-cancerous polyp on the inner lining of the colon or rectum. A tumour is an abnormal tissue and can be benign (not cancer) or malignant (cancer). A polyp is a benign and non-cancerous tumour. Some polyps can change into cancer but not all the polyps do. The chance of changing a polyp into a cancer depends on the kind of polyp

Colorectal cancer is the 3rd most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers). It is the 2nd leading cause of death from cancer in men and the 3rd leading cause of death from cancer in women in Canada.

Incidence is the total number of new cases of cancer. Mortality is the number of deaths due to cancer.

It is estimated that in 2015:

25,100 Canadians will be diagnosed with colorectal cancer. This represents 13% of all new cancer cases in 2015.
9,300 Canadians will die from colorectal cancer. This represents 12% of all cancer deaths in 2015.
14,000 men will be diagnosed with colorectal cancer and 5,100 will die from it.
11,100 women will be diagnosed with colorectal cancer and 4,200 will die from it.
On average, 69 Canadians will be diagnosed with colorectal cancer every day.
On average, 25 Canadians will die from colorectal cancer every day.

The death rate (the number of deaths per 100,000 people per year) because of the colorectal cancer has been reducing in both men and women for more than 20 years. There are many comparable reasons for this. One is those polyps are found by screening and removed before they develop into cancers. Screening allows more colorectal cancers to be found earlier when the disease is easier to cure. In addition, the treatment for colorectal cancer has improved from the last several years. Therefore, there are more than 1 million survivors of colorectal cancer in the United States.

Survival rates are often used by doctors as a typical way of discussing a person's prognosis. The 5-year observed survival rate mentions to the percentage of patients who live at least 5 years after their cancer is diagnosed. Certainly, many people live much longer than 5 years and many are cured.

Relative survival rates, like those in the table, compare the observed survival rate with what would be expected for people without the cancer. This helps to prevent the deaths caused by something besides cancer and is a better way to see the effect that the cancer has on survival.

In order to get survival rates of five years, doctors have to look at the people who were treated years ago and the Improvements in treatment so that it may result in more favourable outlook for people now being diagnosed with colorectal cancer.

Survival rates are often based on previous outcomes of large number of people who had the disease, but they were unable to predict what will happen in any of the particular person's case. Knowing the form and the phase of a person's cancer is important in estimating their outlook. But many other causes can also affect a person's outlook, such as the position of the cancer, the genetic variations in the cancer cells, the treatment received, and how the cancer responds to treatment. Even when we take these factors into consideration survival rates are at best coarse estimates.

Survival rates for colon cancer, by stage:

The numbers below come from the National Cancer Institute's SEER database, looking at people diagnosed with colon cancer between 2004 and 2010.

Figure: 1

*These numbers are correct: patients with stage IIIA or IIIB cancers have better survival than those with stage IIB cancers.

These statistics are based on a previous version of the staging system. In that version, there was no stage IIC (those cancers were grouped considered stage IIB). Also, some cancers that are now considered stage IIIC were classified as stage IIIB, while some other cancers that are now considered stage IIIB were classified as stage IIIC.

Survival rates for rectal cancer, by stage:

The numbers below come from the National Cancer Institute's SEER database, looking at people diagnosed with rectal cancer between 2004 and 2010.

*These numbers are correct; survival was better for some stage III cancers than for some stage II cancers.

These statistics are based on a previous version of the staging system. In that version, there was no stage IIC (those cancers were considered stage IIB). Also, some cancers that are now considered stage IIIC were classified as stage IIIB, while some other cancers that are now considered stage IIIB were classified as stage IIIC.

Figure: 2

Scope and Importance of Colorectal Cancer Research:

Regular colorectal cancer screening or testing is one of the most powerful weapons for preventing colorectal cancer. The regularity rate of colorectal cancer has been falling for about the last 20 years. This is expected to be in large part due to screening (looking for cancer in people who have no symptoms of the disease). The diagnosis of colorectal tests can also find polyps, which will be able to be removed before they develop into cancers. The Research of Colorectal cancer involves the study of specific genetic alterations which are associated with the development and progress of colorectal cancer. By aiming on a specific area of the chromosome associated with colon cancer, called 20-q, we can detect 10 possible candidate genes that could potentially play significant roles in colon cancer. Some of these findings may lead to new approaches in the treatment of colorectal cancer.

By assessing Avastin, a growth inhibitor in cancer cells, it led to the first clinical translational study which evaluates its efficacy on colon cancer patients. In addition, EIF funding was used to help establish the community-based Clinical Cancer Research Network at UCLA, which provides critically important systems to translate new and innovative ideas into clinical testing. Evaluating the role of prostaglandins such as PGE2, a signalling molecule produced by cancer cells in very high levels, and identified several new genes regulated by it. One of those genes is called NR4A2, which has been shown to be instrumental in controlling cancer cell death. Another newly identified gene called GRO alpha was shown to inhibit colorectal tumour growth upon activation. These findings could be potentially important clinically because antibodies directed against these genes may be useful for the treatment of patients with colorectal cancer. According to the scientists, carrying out this kind of experiment is very high risk and would not be supported by other funding mechanisms. Thus, the support from EIF has been crucial. Increased levels of folic acids and vitamin-D are two of the most promising factors which could prevent colon cancer. Other factors include, being physically active and fit, avoid smoking, and reduce red meat consumption. Researchers have developed a test that can find areas of colon cancer spread in nearby lymph nodes that wouldn’t have been found with the test normally used. By recognizing a kind of RNA that is found in colon cancer but not in normal lymph node cells, this may help identify patients who have a higher stage of colon cancer than originally suspected, and who might benefit from chemotherapy after surgery.

Much of our understanding of the fundamental genetic and molecular biological processes driving colorectal cancer pathogenesis has come from studies of somatic mutations in sporadic, non-inherited colorectal cancers and germ line mutations in familial and inherited colorectal cancers. The current genetic-based paradigm of colorectal tumourogenesis as described by Vogelstein et al. is partially based on molecular analysis of sporadic primary colorectal cancer in which compounding genetic mutations lead to the transformation of a benign polyp into invasive colorectal cancer. Studies of germ line mutations found in inherited forms of colorectal cancer, such as familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (HNPCC), also helped to shed light on additional genes involved in malignant transformation. One by one, tumour suppressor genes, DNA mismatch repair genes and proto-oncogenes have been identified and their roles elucidated in the progression from normal colonic epithelium to carcinoma.

With the advent of next-generation sequencing (NGS) technology and its associated massive output in DNA sequence, the newfound ability to re-sequence individual cancer genomes opens a new chapter in biomedical cancer research with the potential for future tailoring of medical care. In this article, we will first discuss the current methods for prognosticating and predicting response to chemotherapy in colorectal cancer with a focus on current genetic-based biomarkers. We will then examine the advances in NGS technology and discuss their application to future colorectal cancer research and clinical practice.

Why it’s in Toronto, Canada?

Toronto, the provincial capital of Ontario, Canada, is a large, ethnically diverse city sprawling along Lake Ontario’s north-western shore. Toronto is positioned in the middle of the newly formed Québec-Ontario Life Sciences Corridor - the second largest life sciences cluster in North America. The Corridor plays a major role in the advancement of life sciences discovery and its related commercialization.

Toronto is a leading international centre of business, finance, arts, and culture, and is widely recognized as one of the most multicultural and cosmopolitan cities in the world. The Toronto/Ontario biotech cluster is the largest in Canada with 163 companies. Nearly 50 global pharmaceutical and biotechnology companies have their Canadian headquarters in the Toronto region. Toronto’s Discovery District is a centre of research in biomedicine, It is also home to the Medical and Related Sciences Centre which was created in 2000 to capitalize on the research and innovation strength of the Province of Ontario, There are over forty hospitals located in the City of Toronto. Many of them are also medical research facilities .Princess Margaret Cancer Centre is one of the Top 5 Cancer Research Centres in the World which is located in Toronto. A dynamic metropolis with a core of soaring skyscrapers, all dwarfed by the iconic CN Tower, it also features abundant green spaces, from the orderly oval of Queen’s Park to 400-acre High Park and its trails, sports facilities and zoo.

Toronto is the leading tourism destination in Canada, attracting more than 25 million Canadian, American and international visitors annually (Tourism Toronto, 2012). In 2012, the Toronto region welcomed 9.9 million overnight visitors. Visitors to Toronto spend about $5.1 billion in direct expenditures during their visits. Visitors to the Toronto region support more than 329,000 people who work in tourism and hospitality. Based on 2013 estimates, Toronto welcomed 13.69 million overnight visitors. 1.42 million visitors arrived from overseas markets (all countries other than Canada and the U.S.)

Members associated with Colorectal Cancer Research:

There are Oncologists, Doctors, scientists, researchers, colorectal cancer specialists, professors, Ph.D. professionals, surgeons, gastroenterologists who are associated with the colorectal cancer research. Among the city Toronto there are about 1764 members and among Canada there are about 9000 and in the world there are about 17000 members are associated with the colorectal cancer research.

Hospitals Associated with Colorectal Cancer Research:

It was found that there are about 238 hospitals in Toronto, Ontario which are associated with colorectal cancer research and there are 1,387 hospitals approximately in Canada and there are more than 10000 hospitals all over the world which are associated with colorectal cancer research.

Some of the Hospitals in Toronto, Ontario and Canada:

Princess Margaret Cancer Centre
St. Michael's Hospital is in downtown Toronto

Cancer Care Ontario

The Ottawa Hospital Cancer Centre

Toronto Western Hospital

Windsor Regional Cancer Program

Odette Cancer Centre

Simcoe Muskoka Regional Cancer Centre

Sunny Brook Health science Centre

London Regional Cancer Program

Grand River Regional Cancer Centre

Juravinski Cancer Centre

Carlo Fidani Peel Regional Cancer Centre

Stronach Regional Cancer Centre at Southlake

R.S. McLaughlin Durham Regional Cancer Centre

Mount Sinai Hospital

Cancer Centre of Southeastern Ontario

Northeast Cancer Centre

Regional Cancer Care – Northwest

St. Joseph’s Health Centre

Renascent Treatment Centres

Agulefo, N T C MD

Societies Associated with Colorectal Cancer Research:

There are almost 205 societies in Toronto and 785 societies in Canada and there are approximately 5786 societies which are dealing with the colorectal cancer Research. Some of the societies are:

Colorectal Cancer Association of Canada - CCAC

National Pancreatic Cancer Canada Foundation

Canadian Cancer Society

Ontario - Canadian Cancer Society

The Ewings Cancer Foundation of Canada

Colon Cancer Canada

Colon and rectum cancer - CRS

CURE Childhood Cancer Association

Canadian Diabetes Association

Canadian Association of Gastroenterology

Gastrointestinal Society

Canadian College of Health Service Executives – CCHSE

Canadian Medical Association

Association of obesity and cancer risk in Canada

Canadian Public Health Association

National Association of County and City Health Officials (NACCHO)

Ontario Medical Association

Canadian Association of Occupational Therapists

Health & Wellness Foundation

Industries Associated with Colorectal Cancer Research:

There are 328 Industries in Toronto and 1200 industries in Canada and about 5200 industries all over the world which are associated with colorectal cancer research. Some of the major Industries which are dealing with the manufacturing of drugs for colorectal cancer therapy are listed below:

Novartis Pharmaceuticals Canada

Johnson & Johnson Canada

Pfizer Pharmaceuticals Canada

Mylan

Merck Pharmaceuticals

Actavis Pharma Company

Bayer Pharmaceuticals

GlaxoSmithKline pharmaceuticals Canada

Apotex Inc.

Pharmascience Inc.

Teva Canada

Del Mar Pharmaceuticals

Algorithme Pharma

Anavex Life Sciences

Concordia Healthcare

Enox Biopharma

Nordion

Tekmira Pharmaceuticals

Universities Associated with Colorectal Cancer Research:

A total of 175 Universities were found in Toronto and there are 595 universities in Canada and there are around 5000 universities all over the world.

Some of the universities are:

University of Toronto

McGill University

University of British Columbia (UBC)

Canadian universities

The University of Western Ontario

McMaster University

University of Calgary

University of Manitoba College of Medicine

Memorial University of Newfoundland

University of Ottawa

Queen’s School of Medicine

Toronto School of Medicine

Trinity Medical College

Victoria University Medical Department

Memorial University of Newfoundland Faculty of Medicine

University of Bishop College Faculty of Medicine

Laval University

Dalhousie University

Northern Ontario School of Medicine

Royal College of Physicians and Surgeons

Market Value on Colorectal Cancer Research:

The global in-vitro colorectal cancer screening tests market was valued at USD 559.3 million in 2014 and is likely to grow at a CAGR of 5.2% over the forecast period. Growing incidences of colon and rectal cancer and the introduction of novel screening tests employing genetic testing are the major factors expected to drive the in-vitro colorectal cancer screening tests market over the forecast period. The introduction of government regulations aimed at mandatory application of cancer screening tests, growing demand for novel minimally invasive tests which screen for colorectal cancer using DNA and genetic biomarkers and the increasing prevalence of colorectal cancer are expected to fuel the growth of the market for in-vitro colorectal cancer screening tests. Globally, colorectal cancer (CRC) is the third most prevalent form of cancer. CRC accounts for almost a tenth of all cancer incidences worldwide. This incidence has only been increasing over the last couple of years. Furthermore, the introduction of novel colorectal tests which use biomarkers such as tumour M2-PK marker or which screen for colorectal cancer using methylated genes for screening will witness a growth in market demand throughout the forecast period. The primary factor responsible for this shift in trend can be attributed to by the increased accuracy of screening which these newer genetic tests have to offer. Its market is expected to reach an estimated value of over USD 250.0 million by 2020. According to a report published by W.H.O cancer fatalities are expected to increase from 14 million in 2012 to 22 million in 2020.

This report provides annualized colorectal cancer therapeutics market revenue, cost of therapy, and treatment usage patterns across eight major markets, namely the US, France, Germany, Italy, Spain, UK, Japan and China, from 2013 and forecast to 2023. Key topics covered include pipeline analysis, strategic competitor assessment, unmet needs, remaining commercial opportunities, and current and future players.

Market Growth of Colorectal Cancer Research in the last and upcoming ten years:

Colorectal Cancer (CRC) research market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.

Fund Allotment to Colorectal Cancer Research:

The fund allotment for the colorectal cancer research in Toronto is about $2,95,91,500 and in Canada it is about $5,97,22,400 and all over the world it is about $8,88,97,055.

No. of Physicians, Researchers and Academicians:

There are about 10795 physicians, 2497 Researchers and about 19585 Academicians in Canada and about 34000 physicians, 10951 Researchers and about 55725 Academicians all over the world.

References:

http://www.prnewswire.com/news-releases/colorectal-cancer-treatment-market-value-to-exceed-9-billion-by-2020-508116511.html

http://www.drug-dev.com/Main/Back-Issues/Colorectal-Cancer-Treatment-Market-Value-to-Hit-94-846.aspx

http://www.reuters.com/article/2015/03/23/research-and-markets-idUSnBw235511a+100+BSW20150323

http://www.pharmaasia.com/article/apac-colorectal-cancer-therapeutics-market-value-to-reach-us-3b-by-2020/11177

http://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market

http://www.grandviewresearch.com/industry-analysis/super-resolution-microscopes-industry

https://www.pancan.org/wp-content/uploads/2013/01/incidence_report_2012.pdf

http://cancer.dartmouth.edu/support_services/documents/cancer_websites_april2011.pdf

http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/

http://chemoth.com/economics

http://www.cancerindex.org/clinks7.htm

http://www.ccalliance.org/

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 16-18, 2017
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2
Poster Opportunity Closed	Click Here to View

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

International Conference on Gastrointestinal Cancer and Therapeutics October 16-18, 2017 Baltimore, USA

Recommended Global Oncology & Cancer Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

GI Cancer 2017

Members associated with Colorectal Cancer Research:

Colorectal Cancer Association of Canada - CCAC

National Pancreatic Cancer Canada Foundation

Canadian Cancer Society

Ontario - Canadian Cancer Society

The Ewings Cancer Foundation of Canada

Colon Cancer Canada

Colon and rectum cancer - CRS

CURE Childhood Cancer Association

Novartis Pharmaceuticals Canada

Johnson & Johnson Canada

Pfizer Pharmaceuticals Canada

Mylan

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues